Skip to navigation Skip to content

News release

Apotex announces launch of the Apotex Global Health Access Fund to promote health equity with $250,000 in annual funding to the Rexdale Community Health Centre

Dec 10, 2024

Toronto, Ontario - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced the launch of the Apotex Global Health Access Fund to support programs that promote health equity and address the root causes of health disparities.

Building on Apotex's legacy of giving, including Apotex's global medicine donation program, the Apotex Global Health Access Fund launches with a focus on addressing unequal access to care and low health literacy within communities where there are poor social determinants of health, and where race, economic status, and other factors are barriers to access.

In its inaugural year, the Apotex Global Health Access Fund will focus on funding maternal health programs in Canada, the United States, India, and Mexico with an annual budget of $1 million. 

The first recipient of an Apotex Global Health Access Fund grant is the Rexdale Community Health Centre (Rexdale CHC) in Toronto. The Rexdale CHC will receive $250,000 annually over three years to support prenatal and postnatal programs, with a focus on providing much-needed wraparound services to the North Etobicoke community in its clinics and through its recently launched Mobile Health Clinic.  

"We are thrilled to launch the Apotex Global Health Access Fund, which underscores our commitment to addressing health inequities and supporting the most vulnerable populations in our key global markets. By focusing on maternal health in our first year, we aim to make a significant impact on the well-being of mothers and their families," said Allan Oberman, President & CEO, Apotex. "The Rexdale Community Health Centre plays a key role in delivering much-needed health services to North Etobicoke residents. As we celebrate Apotex's 50th anniversary, we are honoured to contribute to our local community, and to provide opportunities for our colleagues to do the same."

"We are honoured to be the first recipient of the Apotex Global Health Access Fund. This support will enable us to enhance our maternal health programs and provide critical services to the women in our community. Together, we can work towards a future where every mother has access to the care she needs," said Safia Ahmed, Executive Director of Rexdale Community Health Centre.

For more information about the Rexdale Community Health Centre, please click here.

About Apotex

Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceutical products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at www.apotex.com.

Media inquiries: Contact Apotex Media, [email protected]

Media inquries

Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.

Contact our media team

Latest news

  • Oct 9, 2026

    Apotex to announce second quarter fiscal 2027 financial results and host conference call on Nov. 12, 2026

    TORONTO, Oct. 8, 2026 /CNW/ -- Apotex Health Corp.("Apotex") (TSX: APTX) today announced that it will issue a press release with its second quarter Fiscal 2027 financial results on Thursday, November 12, 2026, at approximately 6:00 a.m. ET. Apotex will host a conference call and live webcast to discuss the results at 8:00a.m. ET.

  • Oct 5, 2026

    Apotex Health Corp. announces closing of $1,250 million inaugural senior unsecured notes offering

    Toronto, Ontario, October 5, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today the closing of the previously announced offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Offering was made through a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.

  • Sep 29, 2026

    Apotex Health Corp. announces $1,250 million inaugural senior unsecured notes offering

    Toronto, Ontario, September 28, 2026 – Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today that it has priced a private placement offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal amount of 5.133% senior unsecured notes, Series 3 due October 5, 2033. The Notes are being offered on an agency basis by a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets, and National Bank of Canada Capital Markets, as co-managers.